Avanir Pharmaceuticals' (AVNR) Shares Cut In Half
Avanir Pharmaceuticals' (NASDAQ:AVNR - News) shares plunged 46% after the San Diego-based company said it has received an approvable letter from the Food and Drug Administration for Zenvia for the treatment of involuntary emotional expression disorder. The company submitted a new drug application for Zenvia in January 2006. "We will be working closely with the agency to determine the next steps required for the drug to receive marketing approval," said Eric Brandt, Avanir's president and chief executive, in a statement.
posted by Stock Administrator @ 10:47 PM
0 Comments:
Post a Comment
<< Home